Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Sells $185,145.00 in Stock

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total transaction of $185,145.00. Following the completion of the transaction, the chief executive officer now directly owns 425,525 shares of the company’s stock, valued at $52,522,550.75. This trade represents a 0.35 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Jazz Pharmaceuticals Stock Up 0.6 %

Shares of NASDAQ:JAZZ opened at $122.54 on Wednesday. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $134.17. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The business’s 50-day moving average is $121.45 and its 200-day moving average is $113.89. The company has a market capitalization of $7.41 billion, a price-to-earnings ratio of 17.26, a P/E/G ratio of 1.04 and a beta of 0.56.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. Rubric Capital Management LP bought a new stake in shares of Jazz Pharmaceuticals in the 2nd quarter valued at $65,812,000. Pacer Advisors Inc. increased its stake in Jazz Pharmaceuticals by 40.7% in the second quarter. Pacer Advisors Inc. now owns 1,820,913 shares of the specialty pharmaceutical company’s stock valued at $194,346,000 after purchasing an additional 527,187 shares in the last quarter. Baupost Group LLC MA raised its holdings in shares of Jazz Pharmaceuticals by 52.8% during the second quarter. Baupost Group LLC MA now owns 1,274,248 shares of the specialty pharmaceutical company’s stock valued at $136,000,000 after purchasing an additional 440,552 shares during the period. Millennium Management LLC boosted its position in shares of Jazz Pharmaceuticals by 1,808.4% during the 2nd quarter. Millennium Management LLC now owns 450,872 shares of the specialty pharmaceutical company’s stock worth $48,122,000 after purchasing an additional 427,246 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of Jazz Pharmaceuticals by 48.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,222,198 shares of the specialty pharmaceutical company’s stock valued at $130,447,000 after buying an additional 398,549 shares during the period. 89.14% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Needham & Company LLC restated a “buy” rating and issued a $207.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Piper Sandler reissued an “overweight” rating and set a $163.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. TD Cowen dropped their target price on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Royal Bank of Canada restated an “outperform” rating and set a $179.00 price target on shares of Jazz Pharmaceuticals in a report on Tuesday, December 10th. Finally, HC Wainwright reiterated a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. Two investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $177.00.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.